Schmid Y

Division of Clinical Pharmacology and Toxicology, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.

Schmid Y

Effects of repeated low-dose LSD on neuropsychological functioning in adults with ADHD: a randomized placebo-controlled study.

Development of the MDMA-Assisted Psychotherapy Side Effects Tool (M-SET): a Delphi study.

The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research.

Psychedelic-Assisted Therapy in Palliative Care-Insights from an International Workshop.

Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program.

Pharmacokinetics, Pharmacodynamics, and Urinary Recovery of Oral Mescaline Hydrochloride in Healthy Participants.

Caffeine, nicotine, cannabis, and psilocybin: Pharmacology, toxicology, and potential therapeutic uses of four naturally occurring psychoactive substances.

Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial.

Editorial: Beyond psilocybin: exploring the clinical potential of alternative and novel psychedelics.

Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers.

Low (micro)doses of 2,5-dimethoxy-4-propylamphetamine (DOPR) increase effortful motivation in low-performing mice.

Safety pharmacology of acute mescaline administration in healthy participants.

Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects.

Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.

Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants.

Altered States and Social Bonds: Effects of MDMA and Serotonergic Psychedelics on Social Behavior as a Mechanism Underlying Substance-Assisted Therapy.

A non-hallucinogenic LSD analog with therapeutic potential for mood disorders.

Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants.

Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis.

Acute subjective effects in LSD- and MDMA-assisted psychotherapy.

Long-lasting subjective effects of LSD in normal subjects.

Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects.

Alterations of consciousness and mystical-type experiences after acute LSD in humans.

LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality.